本文报道了首次开发的电化学生物平台，用于测定人源内皮抑素（HE），该生物标志物具有被认可的抗血管生成潜力，其循环水平升高与侵袭性癌症的发展有关。开发的电分析生物工具结合了使用磁性微粒进行夹心免疫测定和一次性碳电极进行安培转换的优势。展示了34.1 pg/mL的HE标准的检测限（LOD）和适合进入临床肿瘤学领域的选择性。对于在不同阶段的结直肠癌（CRC）患者的细胞裂解物、分泌物、血浆和组织样品等临床样品中HE的测定已取得令人满意的结果，显示了该方法在区分细胞转移能力、鉴定和分期CRC患者方面的能力。开发的生物平台可以进行精确的定量测定，仅需最少的预处理和样品数量，时间仅为75分钟。此外，由于仪器和检测步骤中使用的基板类型，该生物工具与多重化和/或即时需求设备的实施是兼容的，这些特性使其相对于酶联免疫吸附试验（ELISA）或免疫印迹技术具有优势。 © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

This work reports the first electrochemical bioplatform developed for the determination of human endostatin (HE), a biomarker with recognized antiangiogenic potential whose elevated circulating levels have also been associated with the development of aggressive cancers. The developed electroanalytical biotool combines the benefits of using magnetic microparticles for the implementation of sandwich immunoassays and amperometric transduction on disposable carbon electrodes. A limit of detection (LOD) of 34.1 pg mL-1 for HE standards and a selectivity suitable for its foray into the clinical oncology area, are demonstrated. The determination of HE in clinical samples such as lysates and secretomes of colorectal cancer (CRC) cells, plasma, and tissue samples from patients with CRC in different stages, has been faced with satisfactory results showing the ability for discriminating the metastatic capabilities of cells and for identifying and staging CRC patients. The developed bioplatform allows precise quantitative determinations, requiring minimal pre-treatments and sample amounts in only 75 min. In addition, due to the instrumentation and the type of substrates used in the detection step, the biotool is compatible with implementation in multiplexed and/or point-of-need devices, features in which this bioplatform is advantageous with respect to the enzyme linked immunosorbent assay (ELISA) or immunoblotting technologies.Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.